(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803...
Stats | |
---|---|
今日成交量 | 258 592 |
平均成交量 | 639 167 |
市值 | 38.63M |
EPS | $-0.180 ( 2021-08-02 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.38 |
ATR14 | $0.168 (5.73%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-08-18 | Armistice Capital, Llc | Buy | 20 000 | Common Stock |
2021-08-16 | Armistice Capital, Llc | Buy | 30 000 | Common Stock |
2021-07-01 | Cola Michael F | Buy | 51 740 | Stock Option (Right to Buy) |
2021-06-30 | Bruhn Suzanne Louise | Buy | 3 465 | Stock Option (Right to Buy) |
2021-06-30 | Kaplan Gilla | Buy | 6 353 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
0.00 |
Last 95 transactions |
Buy: 9 414 351 | Sell: 408 195 |
音量 相关性
Cerecor Inc 相关性 - 货币/商品
Financial Reports:
No articles found.
Cerecor Inc
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。